Trial Profile
Capecitabine (Xeloda) in malignant mesothelioma: a phase II study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2005 New trial record.